LABS — Life Science Reit Cashflow Statement
0.000.00%
- £156.80m
- £273.47m
- £20.31m
- 46
- 37
- 75
- 52
Annual cashflow statement for Life Science Reit, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | 7.73 | -26.9 | -14.6 | -7.79 |
Non-Cash Items | -8.12 | 31.3 | 23.2 | 17.4 |
Other Non-Cash Items | ||||
Changes in Working Capital | 3.92 | -5.46 | -0.961 | 3.33 |
Change in Accounts Receivable | ||||
Change in Payable / Accrued Expenses | ||||
Cash from Operating Activities | 3.54 | -1.09 | 7.62 | 12.9 |
Capital Expenditures | — | -7.64 | -24 | -19.3 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | -182 | -179 | 12.4 | 2.93 |
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -182 | -186 | -11.6 | -16.4 |
Financing Cash Flow Items | -6.06 | -4.39 | -10.5 | -12.3 |
Other Financing Cash Flow | ||||
Total Cash Dividends Paid | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 344 | 67.1 | -27.2 | -5.34 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 166 | -120 | -31.3 | -8.77 |